Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check8 days agoChange DetectedMetadata and related topics were updated, and the revision tag was changed from v3.6.2 to v3.6.3. These changes adjust navigation and context without altering the study details.SummaryDifference0.2%

- Check15 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2 to reflect a new build. This update records the updated software version without changing the page’s content or functionality.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded related topic tags for Melanoma and MedlinePlus Genetics. These additions connect the study page with broader melanoma-related and genetics resources, providing quick access to contextual materials.SummaryDifference0.2%

- Check30 days agoChange DetectedThe page now indicates that the study is no longer recruiting participants and adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment label was updated to Intervention/Treatment and the site revision is updated to v3.6.0 from v3.5.5.SummaryDifference0.4%

- Check37 days agoChange DetectedThe page revision was updated to v3.5.5 and certain unrelated topics (e.g., Melanoma and MedlinePlus Genetics) were removed from the related topics, reflecting metadata cleanup rather than a change to study details.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now includes Melanoma as a related topic and adds a MedlinePlus Genetics section under related topics. These additions provide quick access to melanoma-related information and genetics resources without changing the study details.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.